株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

PharmaPoint:黄斑浮腫 (ME) と黄斑変性症 (MD) - 現在・将来の主要企業

PharmaPoint: Macular Edema and Macular Degeneration - Current and Future Players

発行 GlobalData 商品コード 325952
出版日 ページ情報 英文 85 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GlobalData社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
PharmaPoint:黄斑浮腫 (ME) と黄斑変性症 (MD) - 現在・将来の主要企業 PharmaPoint: Macular Edema and Macular Degeneration - Current and Future Players
出版日: 2014年10月31日 ページ情報: 英文 85 Pages
概要

当レポートでは、世界の黄斑浮腫 (ME) と黄斑変性症 (MD) の治療薬市場について調査分析し、市場を形成する主要企業 (新規参入企業を含む) に焦点を当てて、競合情勢について、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

第3章 市場の見通し

  • 世界市場
    • 予測
    • 促進要因と障壁

第4章 現在・将来の主要企業

  • 概要
  • 企業戦略の動向
  • 企業プロファイル
    • Roche/Genentech
    • Novartis
    • Regeneron
    • Bayer
    • Valeant
    • Allergan
    • Alimera Sciences
    • Ampio Pharmaceuticals
    • Ophthotech
    • Acucela
    • Ohr Pharmaceuticals

第5章 付録

図表

目次
Product Code: GDHC1040FPR

GlobalData has released its pharma report, "PharmaPoint: Macular Edema and Macular Degeneration - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Macular Edema and Macular Degeneration. The report identifies and analyses the key companies shaping and driving the global Macular Edema and Macular Degeneration market. The report provides insight into the competitive Macular Edema and Macular Degeneration landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

  • Investigation of current and future market competition for Macular Edema and Macular Degeneration
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of Macular Edema and Macular Degeneration sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving Macular Edema and Macular Degeneration market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What's the next big thing in the global Macular Edema and Macular Degeneration market landscape? Identify, understand and capitalize

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Related Reports

3. Market Outlook

  • 3.1. Global Markets
    • 3.1.1. Forecast
    • 3.1.2. Drivers and Barriers - Global Issues

4. Current and Future Players

  • 4.1. Overview
  • 4.2. Trends in Corporate Strategy
  • 4.3. Company Profiles
    • 4.3.1. Roche/Genentech
    • 4.3.2. Novartis
    • 4.3.3. Regeneron
    • 4.3.4. Bayer
    • 4.3.5. Valeant
    • 4.3.6. Allergan
    • 4.3.7. Alimera Sciences
    • 4.3.8. Ampio Pharmaceuticals
    • 4.3.9. Ophthotech
    • 4.3.10. Acucela
    • 4.3.11. Ohr Pharmaceuticals

5. Appendix

  • 5.1. Bibliography
  • 5.2. Abbreviations
  • 5.3. Methodology
  • 5.4. Forecasting Methodology
    • 5.4.1. Diagnosed ME and AMD Patients
    • 5.4.2. Percentage of Drug-Treated Patients
    • 5.4.3. General Pricing Assumptions
  • 5.5. Primary Research - KOLs Interviewed for this Report
  • 5.6. Primary Research - High-Prescribers Survey
  • 5.7. About the Authors
    • 5.7.1. Analyst
    • 5.7.2. Therapy Area Director
    • 5.7.3. Global Head of Healthcare
  • 5.8. About GlobalData
  • 5.9. Disclaimer

List of Tables

  • Table 1: Global Sales Forecast ($m) for ME, 2013-2023
  • Table 2: Global Sales Forecast ($m) for AMD, 2013-2023
  • Table 3: ME and AMD Markets - Drivers and Barriers, 2013-2023
  • Table 4: Key Companies in the ME and AMD Markets in the 7MM, 2014
  • Table 5: Roche/Genentech's ME and AMD Portfolio Assessment, 2014
  • Table 6: Novartis' ME and AMD Portfolio Assessment, 2014
  • Table 7: Regeneron's ME and AMD Portfolio Assessment, 2014
  • Table 8: Bayer's ME and AMD Portfolio Assessment, 2014
  • Table 9: Valeant's AMD Portfolio Assessment, 2014
  • Table 10: Allergan's ME and AMD Portfolio Assessment, 2014
  • Table 11: Alimera Sciences' ME Portfolio Assessment, 2014
  • Table 12: Ampio's ME Portfolio Assessment, 2014
  • Table 13: Ophthotech's AMD Portfolio Assessment, 2014
  • Table 14: Acucela's AMD Portfolio Assessment, 2014
  • Table 15: Ohr Pharmaceutical's AMD Portfolio Assessment, 2014
  • Table 16: Surveyed High-Prescribing Physicians (Non-KOLs), by Country

List of Figures

  • Figure 1: Global Sales for ME by Region, 2013-2023
  • Figure 2: Individual Drug Sales for ME 2013-2023
  • Figure 3: Global Sales for AMD by Region, 2013-2023
  • Figure 4: Individual Drug Sales for AMD 2013-2023
  • Figure 5: Global Sales of Branded Products for ME and AMD by Company, 2013-2023
  • Figure 6: Company Portfolio Gap Analysis in ME and AMD, 2013-2023
  • Figure 7: Roche/Genentech's SWOT Analysis in ME and AMD, 2013-2023
  • Figure 8: Novartis' SWOT Analysis in ME and AMD, 2013-2023
  • Figure 9: Regeneron's SWOT Analysis in ME and AMD, 2013-2023
  • Figure 10: Bayer's SWOT Analysis in ME and AMD, 2013-2023
  • Figure 11: Valeant's SWOT Analysis in AMD, 2013-2023
  • Figure 12: Allergan's SWOT Analysis in ME and AMD, 2013-2023
  • Figure 13: Alimera Sciences' SWOT Analysis in ME, 2013-2023
  • Figure 14: Ampio's SWOT Analysis in ME, 2013-2023
  • Figure 15: Ophthotech's SWOT Analysis in AMD, 2013-2023
  • Figure 16: Acucela's SWOT Analysis in AMD, 2013-2023
  • Figure 17: Ohr Pharmaceutical's SWOT Analysis in AMD, 2013-2023
Back to Top